Avaí Bio, a microcap biotech firm based in Vilnius, is pioneering a novel approach to longevity by targeting the α-Klotho protein, which diminishes with age and is implicated in various age-related conditions. Collaborating with Singapore’s Austrianova through their joint venture, Klothonova, they are developing a method to produce α-Klotho continuously within the body using genetically modified encapsulated cells. This innovative strategy aims to create a self-sustaining “protein generator” that could mitigate the need for constant dosing, thereby addressing the challenges of protein delivery and stability in therapeutic applications.

The significance of this approach lies in α-Klotho’s multifaceted role in aging. Research indicates that higher levels of this protein correlate with extended lifespans and improved physiological function. Its absence accelerates aging-related deterioration across multiple systems, including cardiovascular health and cognitive function. By leveraging encapsulated cell technology, Avaí Bio aims to provide a long-term solution to maintaining α-Klotho levels, potentially shifting the paradigm from treating individual age-related diseases to addressing the underlying biology of aging itself.

This development underscores a broader trend in the biotech sector, where companies are increasingly focusing on cell-based therapies and metabolic health as pivotal factors in aging. With other firms like Lineage Cell Therapeutics and Ocugen also exploring scalable cell platforms and gene therapies, the landscape is evolving rapidly. If successful, Avaí Bio’s approach could not only accelerate timelines for drug development but also redefine how we conceptualize and target aging in therapeutic contexts, moving it from a background concern to a primary focus in longevity research.

Source: longevity.technology